Disclosures for "Comparative Efficacy of Endovascular Techniques for M2 Segment Middle Cerebral Artery Occlusion Stroke: A Systematic Review and Network Meta-analysis"
-
Dr. Alvarez Falcon has nothing to disclose.
-
Author has nothing to disclose
-
Mr. Barbosa has nothing to disclose.
-
Mr. Neves has nothing to disclose.
-
Miss Correia Maciel has nothing to disclose.
-
Dr. Mulatu has nothing to disclose.
-
Dr. Catapano has nothing to disclose.
-
Adam Dmytriw has nothing to disclose.
-
Dr. Regenhardt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genomadix. Dr. Regenhardt has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Rapid Medical. Dr. Regenhardt has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Johnson and Bell Trial Lawyers. Dr. Regenhardt has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Buckley, Theroux, Kline, & Cooley Trial Lawyers. The institution of Dr. Regenhardt has received research support from National Institutes of Health. The institution of Dr. Regenhardt has received research support from Society of Vascular and Interventional Neurology. The institution of Dr. Regenhardt has received research support from Heitman Foundation.